X

Drug Profile

RG 201

Alternative Names: RG 001

Latest Information Update: 18 Jul 1996

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator University of North Carolina
Developer Pharm-Eco Laboratories; Questcor Pharmaceuticals; University of North Carolina
Class Antifungals; Small molecules
Mechanism of Action DNA synthesis inhibitors; Type II DNA topoisomerase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Giardiasis; Pneumocystis pneumonia

Most Recent Events

18 Jul 1996 Discontinued-I for Pneumocystis pneumonia in USA (Unknown route)
18 Jul 1996 Discontinued-Preclinical for Giardiasis in USA (Unknown route)
31 Oct 1995 Preclinical development for Giardiasis in USA (Unknown route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com